INTRODUCTION: Dabigatran etexilate is now prescribed for 51% of the patients receiving oral anticoagulation treatment in New Zealand. Its prescribing trends in relation to patient outcomes are, however, largely unknown for these patients.
Introduction
Dabigatran, a direct thrombin inhibitor, has been available in New Zealand and fully subsided since July 2011. Following its introduction, it has been rapidly adopted, with 51% of patients receiving oral anticoagulation now being treated with dabigatran. 1 This rapid adoption can be partly attributed to dabigatran having very few interactions with other medications and food, along with minimal requirement for routine laboratory monitoring. 2 Treatment with dabigatran is complicated because of the limited knowledge of its realworld safety and efficacy, such as its use for the prevention of thromboembolic events in different patient populations. 3 Depending on clinical risk factors, the dose of dabigatran can be affected by several patient variables. Currently, the 304 VOLUME 10 • NUMBER 4 • DEcEMBER 2018 J OURNAL OF PRIMARY HEALTH CARE New Zealand-approved medicines datasheet recommends a dose of 150 mg twice daily for all indications, except for the treatment of nonvalvular atrial fibrillation in patients aged >75 years. 4 For patients aged 75-80 years, the dose may be reduced to 110 mg twice daily if the perceived thromboembolic risk is low while the risk of haemorrhage is high. 4 For patients aged >80 years, the recommended dose is 110 mg twice daily. 4 Although there are some international data on the use of dabigatran, [5] [6] [7] [8] New Zealand prescribing trends for dabigatran are largely unknown. There is limited data relating to adverse outcomes such as haemorrhage or thromboembolism in patients prescribed dabigatran in New Zealand. 9 Also, there are no reported investigations of outcomes from dabigatran use and patients' demographic characteristics at regional or national levels.
The aim of this population study was to describe current use, effectiveness and safety of treatment with dabigatran in the New Zealand population.
Methods

Identification of study cohort
A retrospective cohort study using administrative health data from New Zealand was conducted. The study population included all patients aged ≥18 years who had at least one dispensing of dabigatran during the study period between 1 July 2011 and 31 December 2015. Data from different datasets were linked using patients' encrypted National Health Index code (NHI; a life-long unique identifier for all interactions with the health system) to ensure patient anonymity. Ethical approval was obtained from the University of Otago Ethics Committee (Reference number HD15/054).
Patient information
Patient data were extracted from the Pharmaceutical Collection, 10 which contains prescription details about community pharmaceutical dispensing claims for all nationally funded medicines. It also provides information on patients' gender, date of birth, age, ethnicity, deprivation index score, geographic location via District Health Board (DHB), prescriber type and frequency and quantity of dispensed medicines. Patients were categorised into the following age groups: <65 years, 65-74 years, 75-80 years and >80 years to align to both regulatory and commonly used clinical stratifications. 4, 11, 12 Continuous dabigatran use was defined as one or more prescriptions recorded in the Pharmaceutical Collection, with less than 120 days between dispensings (prescriptions in New Zealand for dabigatran typically provide 90 days' supply and are provided in 30-day amounts). When 120 days or more elapsed between dabigatran prescriptions, participants were recorded as having intermittent treatment with dabigatran.
Patient outcomes
The outcomes of interest were any admission to hospital for a possible adverse event of haemorrhage, or treatment failure of thromboembolism or cerebrovascular accident (CVA); this information was extracted from the National Minimum Dataset (NMDS). 13 Unspecified CVAs were included for any diagnosis without a classification of haemorrhagic or thromboembolic event. The NMDS is the national record of all public and private hospital discharge information, including coded clinical data for admissions of >4 h duration. Recorded diagnoses are coded using the International Classification of Diseases and Related Health Problems Tenth Revision, Australian Modification (ICD-10-a.m.). 14 
WHAT GAP THIS FILLS
What is already known: There has been rapid adoption of dabigatran etexilate in New Zealand since its subsidy in 2011, and it is now prescribed for 51% of the patients receiving oral anticoagulation. 
Results
Patient demographics
Between 1 July 2011 and 31 December 2015, a total of 52,413 patients were initiated on dabigatran treatment. Of these patients, 5321 (10.2%) had intermittent treatment and 31,040 (59.2%) were male. The median age was 72 years (63-79 years) and most patients (38,020; 72.5%) were aged ≥65 years. 4 , P = 0.001. Geographic locations with higher deprivation index scores had greater use of dabigatran per 1000 of population (P = 0.004). A summary of the demographic characteristics of the patients by geographic location is presented in Table 2 .
Prescriber type
Primary health-care physicians initiated dabigatran for 31,384 (59.9%) patients, with this 
Per 1000 of population 
Adverse events requiring hospitalisation
The median follow-up time for participants was 240 days (IQR: 90-690 days). Approximately 1 in 10 patients required hospitalisation due to an adverse event, which was possibly related to dabigatran; there were 2887 (5.5%) haemorrhagic events, 1419 (2.7%) thromboembolic/CVA events and 1170 (2.2%) unspecified CVAs. Stratification of adverse events by geographic location is presented in Table 2 .
The median time to a haemorrhagic event was 240 days (IQR: 65-630 days); median time to thromboembolic/CVA events was 267 days (IQR: 78-613 days); and an unspecified CVA was 280.5 days (IQR: 81-640 days).
The median age for a haemorrhagic event was 76 years (IQR: 68-82 years); thromboembolism/ CVA 78 years (IQR: 70-83 years); and an unspecified CVA was 78 years (IQR: 69-83 years).
Multivariate analysis indicated that the variables significantly associated with an increase in haemorrhagic events were: geographic location, age >80 years, ethnicities of Māori, Pacific Peoples and New Zealand European, deprivation quintiles 4 and 5 and receiving 150 mg formulation ( Table 3) . The variables significantly associated with an increase in thromboembolism/CVA were: geographic location, age >80 years and deprivation quintile 5 ( Table 3) . The variables significantly associated with an increase in unspecified CVA were geographic location, age 75-79 years, age >80 years, ethnicities of Māori and Pacific Peoples and intermittent use ( Table 3) . None of the covariates used in the final models were correlated.
Discussion
This study aimed to produce a more complete picture of the current use, effectiveness and safety of treatment with dabigatran in the New Zealand population. The study highlights that dabigatran is mainly prescribed in primary care to the elderly, and areas with a higher deprivation score have significantly higher usage.
Adverse events
The rate of haemorrhagic adverse events in the current study of 5.5% is lower than reported in the New Zealand Medicines Datasheet. 4 However, we found a higher rate of treatment failure with a thromboembolism/CVA rate of 2.7% in the current study. The association of demographic factors with dabigatran treatment outcomes has not been previously reported for New Zealand patients. This study showed that living in certain geographical locations, living in higher deprivation areas, being aged >80 years and identifying as Māori or Pacific Peoples were all associated with an increased risk for adverse outcomes. While previous studies have shown a relationship between geographic deprivation and poor health outcomes in general for New Zealanders, [15] [16] [17] [18] none have investigated this in relation to dabigatran treatment. This study specifically showed that patients living in more deprived areas are more likely to experience haemorrhagic events that can be attributed to dabigatran. This is consistent with the findings of a New Zealand national health survey that found Māori and Pacific Peoples and people living in the most deprived areas of New Zealand generally report greater unmet health needs than others. 19 To address this issue, additional resources and strategies need to be targeted at these populations during treatment initiation and maintenance.
The time to either adverse event or treatment failure occurs mainly in the first 2 years of treatment. A median time of 120 days (IQR: 30-340 days) to haemorrhagic event has been previously reported only for gastrointestinal haemorrhage. 20 The current study combined all forms of haemorrhagic events and showed that most of these occur in the first 2 years of 308 VOLUME 10 • NUMBER 4 • DEcEMBER 2018 J OURNAL OF PRIMARY HEALTH CARE *Statistically significant.
-Not included in final model. The limitations of this study include the NMDS capturing patient data only for people who required hospitalisation for a duration of >4 h. Therefore, outcomes of interest that did not meet this criterion, for example, a haemorrhage or CVA that resulted in death, would not be included in the dataset, resulting in possible under estimations. Also, there can be errors in the clinical codes entered in the NMDS, resulting in possible inclusion or exclusion of the clinical outcomes of interest. As comorbidities vary between population groups of different ethnicities and as their interaction with dabigatran treatment is not accounted for in this study, there is possible bias in outcome profiles. For example, Māori have a higher prevalence of diabetes and this may attribute to CVA at younger ages. 23 As the NMDS contains no diagnostic information, it was not possible to investigate disease-specific dose regimens by indication. The main strength of this study is the inclusion of a large national cohort of patients, with sufficient sample size to provide adequate information about the effects of demographics on dabigatran outcomes for an entire population.
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The findings of this study demonstrate that dabigatran patients of Māori and Pacific Peoples ethnicity are at greater risk of harm than people of other ethnicities.
Conclusion
We have provided new evidence that demographic factors can directly affect outcomes for people treated with dabigatran and real-world evidence for when these events occur. Improvement of outcomes could be achieved by increased vigilance of clinical monitoring, especially in the Māori and Pacific Peoples populations, the elderly and people living in more deprived areas.
